MUMBAI, India, Aug. 17 -- Intellectual Property India has published a patent application (202647094857 A) filed by Astellas Pharma Inc. on August 05, 2026, for Antibody-Drug Conjugate Containing Heterocyclic Compound Having Activity Of Inducing Decomposition Of Kras Mutant Proteins.
Inventors include Yamashita, Yu; Sugane, Takashi; Morikawa, Takahiro; Imada, Sunao; Hamaguchi, Hisao; Okumura, Mitsuaki; Imaizumi, Tomoyoshi; Koganemaru, Yohei; Fujiwara, Yuta; Kawaminami, Eiji; Saito, Asako; and Nishizono, Yoshihiro.
The application for the patent was published on August 14, 2026, under issue no. 33/2026.
Abstract: Provided is an antibody-drug conjugate for use in the treatment of cancer in which one or more KRAS mutants, particularly a KRAS G12V mutant, a KRAS G12D mutant, and a KRAS G12C mutant, are expressed. Also provided are a drug and a drug-linker conjugate for use in the antibody-drug conjugate. The present inventors have produced an antibody-drug conjugate with which a heterocyclic compound represented by formula (II) and having an activity of inducing the decomposition of KRAS mutant proteins can be delivered to cancer in which EGFRs are expressed, the production being achieved by linking the compound to an anti-EGFR antibody. The present inventors have also discovered a drug-linker conjugate for use in the antibody-drug conjugate or a salt thereof. In cancer in which EGFRs are expressed, the antibody-drug conjugate induces the decomposition of one or more KRAS mutants, particularly a KRAS G12V mutant protein, a KRAS G12D mutant protein, and a KRAS G12C mutant protein, thereby inhibiting the KRAS mutants and exhibiting an anti-tumor effect.
Disclaimer: Curated by HT Syndication.
